Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Cardiovascular Outcomes# EXSCEL Trial (Exenatide)# The EXSCEL trial (Holman et al., NEJM 2017) enrolled 14,752 patients with T2D (73.1% with prior CV disease): Primary MACE: HR 0.91 (95% CI 0.83-1.00, p=0.06 for superiority) Non-inferiority achieved
Personalized Holistic Support For POTS POTS is a complex, multi-system approach that requires a multifaceted approach
A licensed provider reviews your information and helps determine whether treatment may be appropriate
Is Semaglutide safe for everyone
US$ 22.68
US$ 25.49
US$ 29.67
US$ 26.88
US$ 26.01
US$ 29.85
US$ 26.50
US$ 25.27
US$ 20.00
US$ 22.65
